Eli Lilly (LLY) has officially set its sights on a first-quarter 2027 submission to the U.S. Food and Drug Administration for retatrutide, a next-generation obesity treatment that some analysts are already calling “surgery-level” therapy. With that timeline now concrete, a more distant debate is gathering momentum on Wall Street: whether the drugmaker’s stock can reach $1,750 by the same year.
Retatrutide’s phase 3 data showed mean weight loss of up to 28.3% over 80 weeks — a result that not only far exceeded what Novo Nordisk’s Wegovy delivered in clinical trials but, as several observers noted, approaches outcomes typically seen with bariatric surgery. The drug acts on three gut hormones, offering a triple-pathway mechanism that produced meaningful weight reductions even in patients with diabetes, a population that generally struggles more to shed pounds. Eli Lilly is also investigating retatrutide in obstructive sleep apnea, chronic back pain, and metabolic dysfunction-associated steatotic liver disease. Management stressed that the new medicine is designed to expand the overall obesity market rather than cannibalize sales of its current blockbuster Zepbound, reinforcing the company’s leadership position.
Financially, Eli Lilly continues to fire on all cylinders. Second-quarter revenue surged 48% year over year to $23 billion, while adjusted earnings per share rose 33% to $8.38. The company raised its full-year revenue guidance to a range of $85 billion to $87 billion. Behind the headline numbers, however, realized prices dropped roughly 13% overall, with U.S. prices down around 9%, and $2.78 billion in acquired in-process research and development charges pushed the effective tax rate to 23.3%. Those factors, alongside the stock’s low beta, have kept share price gains muted relative to underlying growth.
The stock is up 9.23% year to date, with the market capitalization holding near $1.1 trillion and shares trading at approximately $1,170. Following the earnings report, several banks lifted their targets: Morgan Stanley now sees $1,419, BMO Capital raised its target to $1,400, and Wells Fargo moved to $1,330, while the consensus analyst target sits at $1,276.96. Of the 28 analysts covering the name, 22 rate it a Buy or Strong Buy. An independent research model puts the base-case target at $1,430.26, with a bull case of $1,639.16.
A more aggressive scenario outlined by some market commentators maps a path to $1,750 by 2027 — a 49.6% gain from current levels. Based on forward earnings per share of $38.14, that price target implies a forward price-to-earnings multiple of about 46 times, compared with the roughly 31 times at which the stock currently trades. The bull case leans on several catalysts: quarterly earnings growth running at 169.9%, a 172% surge in Mounjaro international revenue driven by inclusion on China’s national reimbursement drug list, and a smooth regulatory journey for retatrutide. Yet the blueprint is fragile. Any safety signal in retatrutide’s remaining trials or aggressive Medicare pricing intervention could compress the valuation multiple rapidly.
Eli Lilly enters this multiyear setup with a validated metabolic pipeline and accelerating financial momentum. Still, the run toward $1,750 rests on a sequence of milestones that must hit without a misstep.
